Dr. Shawn He Named Chief Scientific Officer at Cure Genetics


Cure Genetics is delighted to announce that Dr. Shawn He will officially take up his post as the Chief Scientific Officer (CSO) in cell therapy on August 1, 2023. Shawn will guide the navigation of Cure Genetics' cell therapy development, leading the team to break new ground and accelerate the progress of cell therapy pipelines.

Dr. Shawn He has over two decades of experience in cell therapy research and development, as well as managing R&D teams at leading global biotechnology companies. Before joining Cure Genetics, Shawn served as Executive Vice President of Research and Early Development at Celularity, where he developed a pipeline of novel allogeneic CAR-T and CAR-NK cell therapies, and guided R&D efforts for two different cell therapy products to clinical-stage development. Earlier, Shawn held various positions of increasing scope and responsibility at Celgene Cellular Therapeutics, and his team advanced three cell therapy product candidates into IND-enabling studies with all of them reaching the clinic for eight different indications. Shawn received his PhD from University of Maryland at College Park.

"I look forward to working with the team at Cure Genetics," said Dr. Shawn He. “ Cure Genetics' innovative platform technology, differentiated pipeline, and global strategy all hold significant competitive advantages on a global scale. I firmly believe that Cure's pioneering work in the field of cell and gene therapy will help us discover innovative treatments for cancers and genetic diseases with unmet needs. I look forward to contributing to the development of new treatments alongside the Cure Genetics team."

"On behalf of Cure Genetics, I am delighted to welcome Dr. Shawn He to our team," said the Chairman of Cure Genetics. "Shawn is an outstanding scientist and leader in the field of cell therapy. His extensive experience and spirit of innovation will greatly enhance our innovative capabilities and his forward-thinking international perspective will bring a significant positive impact on our research and development efforts and product pipeline global strategy."

Cure Genetics, established in Suzhou in 2016, is a clinical-stage company dedicated to developing cell and gene therapies for solid tumors and common genetic diseases. Through our innovative technology platforms, including the Universal CAR-NKT platform AIMS CAR-NKTTMand our unique AAV platform VELPTM, Cure Genetics achieves a differentiated pipeline layout, leading the way in original innovation. By leveraging global collaborations and out-license, we actively drive the research & development, and commercialization of innovative drugs. We aim to provide effective treatment measures for patients worldwide with unmet medical needs and to become a benchmark in the global field of cell and gene therapy.